A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B
Jing Li,Haitao Chen,Jiaxuan Chen,Bin Zhou,Jinlin Hou,De-Ke Jiang
DOI: https://doi.org/10.2147/PGPM.S337962
2021-11-23
Pharmacogenomics and Personalized Medicine
Abstract:Jing Li, 1, &ast Haitao Chen, 1, 2, &ast Jiaxuan Chen, 1, &ast Bin Zhou, 1 Jinlin Hou, 1 De-Ke Jiang 1 1 State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China; 2 School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, People's Republic of China &astThese authors contributed equally to this work Correspondence: De-Ke Jiang; Jinlin Hou State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, People's Republic of China Tel +86-20-62786533 ; +86-20-61641941 Email ; Purpose: Granulysin (GNLY) is a cytotoxic granule that has been reported to have various antimicrobial activities. We evaluated the association between a missense variant in GNLY (rs11127) and treatment efficacy of pegylated interferon-alpha (PegIFNα) or nucleos(t)ide analogs (NUCs) in patients with chronic hepatitis B (CHB). Patients and Methods: We included a total of 1823 patients with hepatitis B e antigen (HBeAg)-positive CHB (954 patients treated with PegIFNα and 869 patients treated with NUCs) in four Phase IV multicenter randomized controlled trials. The association of the GNLY rs11127 genotype with the combined response (CR), defined as HBeAg seroconversion and hepatitis B virus (HBV) DNA level < 2000 IU/mL was evaluated. A polygenic score (PGS) was constructed to evaluate the cumulative effect of multiple single-nucleotide polymorphisms (SNPs), including rs11127 and several other SNPs, STAT4 rs7574865, CFB rs12614, and CD55 rs28371597, which were reported to be associated with CR. Results: GNLY rs11127 was significantly associated with CR in patients treated with PegIFNα. The CR rate in patients with the rs11127 CC genotype was higher than that with the CT or TT genotype (40.98% vs 30.34% or 27.09%, P = 0.003). Furthermore, a PGS integrating GNLY rs11127 and three other SNPs was significantly associated with CR in PegIFNα-treated patients ( P < 0.001). However, no significant correlation was found between GNLY rs11127 and CR in NUCs-treated patients. Conclusion: GNLY rs11127 is an independent biomarker for predicting the response to PegIFNα therapy in HBeAg-positive CHB patients. Furthermore, the PGS, including GNLY rs11127, provides new insights for individualized treatment in clinical practice. Keywords: GNLY , rs11127, chronic hepatitis B, PegIFNα treatment, polygenic score Chronic hepatitis B virus (HBV) infection remains a major concern for global health, with an estimated 292 million cases and approximately 30% in China. 1 Because of its high prevalence and severe health consequences, such as cirrhosis and hepatocellular carcinoma (HCC), chronic HBV infection imposes a substantial burden on patients and society. 2 The current first-line antiviral treatments can be classified into two categories: pegylated interferon-alpha (PegIFNα) and nucleos(t)ide analogs (NUCs). 3 NUCs have excellent performance in tolerability, high rates of biochemical remission, and effective inhibition of HBV replication; however, long-term therapies also incur increasing cost, safety profiles and compliance issues. As for PegIFNα treatment, despite its severe adverse reactions, it is also an alternative strategy with considerable efficacy in increasing hepatitis B s antigen (HBsAg) loss and reducing the incidence of cirrhosis and HCC. 4,5 According to the American Association for the Study of Liver Disease (AASLD) 2018 Hepatitis B Guidance, indicators such as HBV DNA suppression, HBeAg seroconversion or loss, normalization of alanine aminotransferase (ALT), and HBsAg loss, are provided to assess the efficacy of first-line antiviral therapies, including PegIFNα. 6 Combined response (CR), defined as HBeAg seroconversion along with HBV DNA level <2000 IU/mL, was also used to evaluate for IFN efficacy. 7,8 Regardless of NUCs or PegIFNα, the therapeutic response rate is limited. Therefore, it is important to identify novel biomarkers to predict the therapeutic efficacy. Accumulating evidence has demonstrated that host genetics could affect the response to IFNα treatment. 9,10 Notably, IL28B p -Abstract Truncated-
pharmacology & pharmacy